meta
|
evidence
oncology
Living systematic review and meta-analysis
limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M)
1
limited stage SCLC (ls-SCLC) - 2nd Line (L2)
melanoma (ML)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
ipilimumab plus gp100
ipilimumab plus SoC
tremelimumab
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib
atezolizumab plus SoC
nivolumab based treatment
nivolumab alone
nivolumab followed by ipilimumab
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (2mg/kg)
pembrolizumab plus SoC
Immune checkpoint association
nivolumab plus ipilimumab
relatlimab plus nivolumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs alkylating agents
vs dacarbazine
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs ipilimumab followed by nivolumab
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs pembrolizumab based treatment
vs pembrolizumab alone
vs Immunostimulant
vs interferon alpha
vs vaccine
vs gp100
vs non active control
vs placebo
All patients
Age < 65y (younger)
Age > 65y
BRAF mutant
BRAF wild type
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
PD-L1 < 1%
PD-L1 > 1%
stage IIIa
stage IIIb
stage IIIc
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
DMFS
DOR
MFS
objective responses (ORR)
PFS (extension)
progression or deaths (PFS)
RFS (extension)
RFS/DFS
AE (any grade)
AE (grade 3-4)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Abdominal pain TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Chills TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Cough TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
Headache TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Myalgia TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Paraesthesia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritic rash TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Sarcoidosis TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vitiligo TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Weight decreased TRAE (grade 3-4)
deaths (OS)
progression or deaths (PFS)
RFS/DFS
mML - NA - all population
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
versus placebo
pembrolizumab alone vs. placebo
1
-
-
0.57
[0.43; 0.75], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
mML - NA - PDL1 positive
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - PDL1 positive
versus placebo
pembrolizumab alone vs. placebo
1
-
-
0.54
[0.42; 0.69], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
mML - L1 - all population
metastatic/adv melanoma (mML)
mML - 1st line (L1)
mML - L1 - all population
mML - L1 - BRAF mutant
metastatic/adv melanoma (mML)
mML - 1st line (L1)
mML - L1 - BRAF mutant
mML - L1 - BRAF wild
metastatic/adv melanoma (mML)
mML - 1st line (L1)
mML - L1 - BRAF wild
mML - L2 - all population
metastatic/adv melanoma (mML)
mML - 2nd line (L2)
mML - L2 - all population
versus ipilimumab alone
pembrolizumab (10mg/kg) vs. ipilimumab alone
1
0.69
[0.52; 0.91], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
0.58
[0.47; 0.72], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
-
pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone
1
0.63
[0.47; 0.84], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
0.58
[0.46; 0.73], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
-
versus Standard of Care (SoC)
pembrolizumab (10mg/kg) vs. Standard of Care (SoC)
1
0.74
[0.57; 0.96], 1 RCT, I2=0%
unassessable degree of certainty
0.50
[0.39; 0.64], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
-
pembrolizumab (2mg/kg) vs. Standard of Care (SoC)
1
0.86
[0.67; 1.10], 1 RCT, I2=0%
inconclusive result
0.57
[0.45; 0.73], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
-
mML - L2 - BRAF mutant
metastatic/adv melanoma (mML)
mML - 2nd line (L2)
mML - L2 - BRAF mutant
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open